BeyondSpring Inc.

Equities

BYSI

KYG108301006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.13 ^USD	-6.17%		+11.52%	+136.67%

Apr. 22	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 15	North American Morning Briefing : Stock Futures -2-	DJ

BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2023

February 02, 2024 at 04:31 pm EST

BeyondSpring Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was USD 0.875 million compared to USD 0.676 million a year ago. Net loss was USD 12.72 million compared to USD 18.49 million a year ago.

Basic loss per share from continuing operations was USD 0.33 compared to USD 0.47 a year ago. Diluted loss per share from continuing operations was USD 0.33 compared to USD 0.47 a year ago.

Latest news about BeyondSpring Inc.

North American Morning Briefing : Stock Futures -2-	Apr. 22	DJ
North American Morning Briefing : Stock Futures -2-	Apr. 15	DJ
BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment	Mar. 25	MT
Beyondspring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in A Phase 2 Investigator-Initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer	Mar. 25	CI
BeyondSpring Inc. Announces Executive Changes	Mar. 18	CI
Top Premarket Decliners	Mar. 06	MT
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	Feb. 02	CI
BeyondSpring Receives Non-Compliance Notice From Nasdaq	Jan. 10	MT
BeyondSpring Receives Notification From Nasdaq for Breaching Minimum Bid Price Requirements	Dec. 19	MT
Transcript : BeyondSpring Inc. - Special Call	Nov. 07
BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin?s Immunomodulating Activity	Nov. 07	CI
BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director	23-07-14	CI
North American Morning Briefing : Traders Bet Data -2-	23-07-12	DJ
North American Morning Briefing : China Data -2-	23-07-05	DJ
North American Morning Briefing : Chip Stocks Take -2-	23-06-28	DJ
BeyondSpring Inc.(NasdaqCM:BYSI) added to Russell Microcap Value Index	23-06-23	CI
BeyondSpring Inc.(NasdaqCM:BYSI) added to Russell 3000E Value Index	23-06-23	CI
North American Morning Briefing: Investors Eye Powell Testimony	23-06-21	DJ
North American Morning Briefing : Focus Fixes on Fed, Powell	23-06-14	DJ
BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT	23-06-07	CI
North American Morning Briefing : China Trade Data -2-	23-06-07	DJ
North American Morning Briefing : Stock Futures -2-	23-05-31	DJ
North American Morning Briefing : Debt-Ceiling -2-	23-05-17	DJ
Baird Adjusts Price Target on BeyondSpring to $1.25 From $4, Maintains Outperform Rating	23-05-02	MT
BeyondSpring Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-18	CI

Chart BeyondSpring Inc.

Duration

Period

More charts

Company Profile

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q4 2023 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
BEYONDSPRING INC.	+136.67%	83.1M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs